Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Amgen $AMGN and its Belgian partners at UCB may have won over the FDA, but the EMA is still not convinced by their bone-building osteoporosis drug romosozumab.